SCHEMBL4862922

SCHEMBL4862922

Cc1cccc(CNc2nc(S(C)(=O)=O)nc3occ(-c4ccccc4)c23)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 8/20 0.39
KCNA5 P22460 9/20 0.35
JAK2 O60674 3/20 0.35
CDK2 P24941 3/20 0.35
TYK2 P29597 3/20 0.35
GSK3B P49841 3/20 0.35
JAK3 P52333 3/20 0.35
BTK Q06187 3/20 0.35
IRAK4 Q9NWZ3 3/20 0.35
CSNK2A2 P19784 2/20 0.35
CCNE1 P24864 2/20 0.35
AURKB Q96GD4 2/20 0.35
IGF1R P08069 1/20 0.35
PIM1 P11309 1/20 0.35
SRC P12931 1/20 0.35
JAK1 P23458 1/20 0.35
FLT4 P35916 1/20 0.35
FLT3 P36888 1/20 0.35
MAP3K8 P41279 1/20 0.35
CSNK1A1 P48729 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4865901 0.87 KCNH2 (0.49) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL4869360 0.82 KCNH2 (0.53) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL4862943 0.82 HPGD (0.47) SMN1; SMN2USP2KMT2A
SCHEMBL4868742 0.73 NPSR1 (0.43) SMN1; SMN2USP2CYP1A2CYP3A4KMT2A
SCHEMBL5246200 0.70 KCNH2 (0.46) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL12170763 0.67 KCNH2 (0.68) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL12170452 0.67 KCNA5 (0.73) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL4867404 0.67 KCNH2 (0.47) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL4862847 0.65 KCNA5 (0.48) KCNH2KCNA5JAK2CDK2TYK2
SCHEMBL4863471 0.65 CDK2 (0.50) KCNH2KCNA5JAK2CDK2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456187-B2 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION LIMITED (GB) 2008-11-25 US disclosed
CN-1964978-A Furanopyrimidine compounds effective as potassium channel inhibitors XENTION LTD (GB) 2007-05-16 CN disclosed
EP-1758909-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS Xention Limited (GB) 2007-03-07 EP disclosed
WO-2005121149-A1 FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2005-12-22 WO disclosed
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors XENTION DISCOVERY LTD. (GB) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282829-A1 Furanopyrimidine compounds as potassium ion channel inhibitors KCNH3, HCN4, KCNH2 KCNH2 3/4885KCNA5 6/4885JAK2 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.